Codiak BioSciences (CDAK) Stock Price, News & Analysis

Company Overview

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $0.0016 to $0.0016
• 50-Day Range: N/A
• 52-Week Range: $0.05 to $6.98
• Volume: N/A
• Average Volume: 1.37 million shs
• Market Capitalization: $58.93 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CDAK Stock Analysis - Frequently Asked Questions

How were Codiak BioSciences' earnings last quarter?

Codiak BioSciences, Inc. (NASDAQ:CDAK) released its quarterly earnings results on Thursday, November, 4th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by $0.12. The company earned $1.16 million during the quarter, compared to the consensus estimate of $2.87 million. Codiak BioSciences had a negative trailing twelve-month return on equity of 109.51% and a negative net margin of 51.13%.

When did Codiak BioSciences IPO?

Codiak BioSciences (CDAK) raised $82 million in an IPO on Wednesday, October 14th 2020. The company issued 5,500,000 shares at $14.00-$16.00 per share. Goldman Sachs, Evercore ISI, William Blair and Wedbush PacGrow served as the underwriters for the IPO.

What other stocks do shareholders of Codiak BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Codiak BioSciences investors own include NIO (NIO), Advanced Micro Devices (AMD), Alibaba Group (BABA), NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA) and Plug Power (PLUG).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 8/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CDAK
• CIK: 1659352
• Web: www.codiakbio.com
• Phone: 617-949-4100
• Fax: N/A
• Employees: 102
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.16 million
• Net Margins: -51.13%
• Pretax Margin: -51.13%
• Return on Equity: -109.51%
• Return on Assets: -34.44%

Debt

• Debt-to-Equity Ratio: 0.66
• Current Ratio: 4.24
• Quick Ratio: 4.24

Sales & Book Value

• Annual Sales: $33.57 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.39 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 36,830,000
• Free Float: 33,810,000
• Market Cap: $58.93 thousand
• Optionable: Not Optionable
• Beta: 3.71